ProAxsis develops laboratory-based immunoassays and point-of-care tests for the measurement of active protease biomarkers of disease based on our proprietary ProteaseTag technology. Our existing respiratory portfolio is being utilised by pharmaceutical companies who are developing protease inhibitors as novel therapeutic options. ProAxsis has gained CE Marks for laboratory assays measuring neutrophil elastase, proteinase 3 and plasmin, enabling monitoring of disease severity and responsiveness to treatment, and is able to develop assays targeting other proteases if required.
Recently, the company registered a CE Mark for a qualitative point-of-care test (NEATstik) for the ongoing monitoring of active neutrophil elastase in patients with respiratory disease. The ProAxsis team is also able to process and analyse clinical samples for various biomarkers at our laboratory in Northern Ireland.